Part 2 of a 2-Part CME Satellite Symposium Series Held in Conjunction with the 2026 American Urological Association Annual Meeting (AUA2026)
Location
Walter E Washington Convention Center
801 Allen Y Lew Place NW
Washington, DC 20001
Phone: (202) 249-3000
Program Schedule — Eastern Time
5:00 PM – 5:30 PM — Registration and Dinner
5:30 PM – 7:30 PM — Educational Meeting
Meeting Room
Ballroom A, Third Level
No registration fee is charged for this event. For the in-person symposium in Washington, DC, preregistration is required to ensure seating.
Faculty
Faculty
Neeraj Agarwal
MD, FASCO
Huntsman Cancer Institute, University of Utah (NCI-CCC) Salt Lake City, Utah
Professor of Medicine Senior Director for Clinical Research Huntsman Cancer Institute Presidential Endowed Chair of Cancer Research Director, Center of Investigational Therapeutics
Faculty
Daniel P Petrylak
MD
Yale School of Medicine New Haven, Connecticut
Professor of Medicine and Urology Director, Genitourinary Oncology Research Program Co-Director, Signal Transduction Program Yale Comprehensive Cancer Center
Faculty
Neal D Shore
MD
AUC Atlantic Urology Specialists Myrtle Beach, South Carolina
Director, START Carolinas/Carolina Urologic Research Center Head of GU Oncology START Research
Faculty
Fred Saad
CQ, MD
University of Montreal Hospital Center (CHUM) Montréal, Québec, Canada
Professor and Chairman Department of Surgery
Moderator
Elisabeth I Heath
MD
Mayo Clinic Rochester, Minnesota
Chair, Department of Oncology
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Merck.
Program Schedule — Eastern Time
5:00 PM – 5:30 PM — Registration and Dinner
5:30 PM – 7:30 PM — Educational Meeting
MODULE 1: Evolving Management of Nonmetastatic Hormone-Sensitive Prostate Cancer (nmHSPC) — Dr Shore
- Rationale for the evaluation of treatment intensificationwith androgen receptor (AR) pathway inhibitors for nmHSPC
- Major efficacy and safety data, including overall survival outcomes, from the Phase III EMBARK trial evaluating enzalutamide with leuprolide versus enzalutamide or leuprolide alone for patients with nmHSPC and high-risk biochemical recurrence after definitive therapy
- FDA approval of enzalutamide with and without androgen deprivation therapy (ADT) and optimal application in clinical practice
- Published data with ADT intensification with apalutamide with or without abiraterone for patients with high-risk, biochemically recurrent nmHSPC
- Other ongoing Phase III studies evaluating AR pathway inhibitors for patients with nmHSPC
MODULE 2: Current Hormonal Treatment for Metastatic HSPC (mHSPC) — Dr Petrylak
- Extended follow-up with abiraterone, enzalutamide and apalutamide in combination with ADT for patients with mHSPC
- Published data from the Phase III ARANOTE study supporting the recent FDA approval of darolutamide/ADT for mHSPC
- Clinical factors guiding the selection of a specific AR pathway inhibitor for patients with mHSPC; availabledatasets exploring the relative benefit of various approved agents
- Published efficacy and safety data from the Phase III ARASENS trial evaluating darolutamide in combination with docetaxel and ADT for mHSPC
- Selection of optimal candidates with mHSPC for triplet therapy with darolutamide/docetaxel/ADT
MODULE 3: Current and Future Role of PARP Inhibitors for Metastatic Prostate Cancer (mPC) — Dr Agarwal
- Incidence and clinical implications of BRCA1/2 and other homologous recombination repair (HRR) abnormalities in patients with mPC; recommended timing and optimal method for genetic testing
- Long-term efficacy and safety findings with olaparib/abiraterone, niraparib/abiraterone and talazoparib/enzalutamide, respectively, in the first-line setting for metastatic castration-resistant prostate cancer (mCRPC)
- FDA-approved indications for olaparib/abiraterone, niraparib/abiraterone and talazoparib/enzalutamide for mCRPC; appropriate selection of a PARP inhibitor/secondary hormonal therapy combination for individual patients
- Published data from the Phase III AMPLITUDE trial evaluating the addition of niraparib to abiraterone/prednisone for mHSPC harboring alterations in HRR genes; recent FDA approval for patients with BRCA2-mutated disease
- Emerging positive findings from the Phase III TALAPRO-3 study assessing talazoparib in combination with enzalutamide versus placebo and enzalutamide for HRR-altered mHSPC
- Mechanistic similarities and differences between saruparib and other PARP inhibitors; ongoing efforts evaluating saruparib for mHSPC and in earlier settings
MODULE 4: Emerging Role of AKT Inhibition for Patients with mHSPC — Dr Heath
- Biological justification for targeting the PI3K/AKT/mTOR pathway with capivasertib in prostate cancer; rationale for benefit in patients with PTEN-deficient disease
- Frequency of PTEN deficiency in prostate cancer; indications for and optimal timing of and approach to PTEN assessment
- Design, eligibility criteria and primary and secondary endpoints of the Phase III CAPItello-281 trial assessing capivasertib with abiraterone/ADT for patients with de novo mHSPC and PTEN deficiency
- Recently presented positive results from CAPItello-281 with the addition of capivasertib to abiraterone/ADT for PTEN-deficient mHSPC
- Spectrum of toxicities associated with capivasertib; recommended monitoring and management strategies
- Potential integration of capivasertib/abiraterone/ADT into mHSPC treatment algorithms; optimal use compared to other currently available regimens
MODULE 5: Current and Future Use of Radiopharmaceuticals for mPC — Dr Saad
- Incidence of prostate specific membrane antigen (PSMA) expression in prostate cancer; current utility in detecting metastatic progression and as a therapeutic target
- Published Phase III datasets with lutetium Lu 177 vipivotide tetraxetan for patients with taxane-naïve and taxane-pretreated, PSMA-positive mCRPC; appropriate sequencing opposite other available therapies
- Recently presented results from the Phase III PSMAddition study evaluating the addition of lutetium Lu 177 vipivotide tetraxetan to hormonal therapy for patients with PSMA-positive mHSPC; implications for clinical practice
- Tolerability/toxicity profile of lutetium Lu 177 vipivotide tetraxetan alone and in combination with AR-targeted therapy/ADT
- Early findings with and ongoing evaluation of other novel radiopharmaceuticals for mPC
Target Audience
This activity has been designed to meet the educational needs of urologists, medical and radiation oncologists, and other allied healthcare professionals involved in the treatment of prostate cancer.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Infer how various clinical and biological factors affect the risk of prostate cancer recurrence after local therapy, and design appropriate treatment plans for individual patients considering the potential benefits and risks of new and established forms of hormonal therapy.
- Appraise published research findings on optimal management approaches for biochemical recurrence after local treatment for prostate cancer, and counsel appropriate patients regarding the potential benefits of FDA-approved systemic treatment options.
- Evaluate the published research database supporting the FDA approvals of secondary hormonal agents for the management of nonmetastatic prostate cancer, and apply this information in the discussion of nonresearch treatment options.
- Explore available data with treatment intensification with cytotoxic therapy, secondary hormonal therapy or combinations of these approaches for metastatic hormone-sensitive prostate cancer (mHSPC), and effectively integrate these strategies into current clinical management algorithms.
- Assess the available research database supporting the use of PARP inhibitors in combination with androgen receptor pathway inhibitors for patients with metastatic prostate cancer harboring a homologous recombination repair gene alteration, and discern how to optimally incorporate these agents into current clinical management algorithms.
- Appreciate the biological rationale for targeting the PI3K/AKT/mTOR pathway for prostate cancer, and evaluate available data with novel AKT inhibitors in combination with hormonal therapy for patients with mHSPC and PTEN deficiency.
- Review available Phase III data documenting the efficacy of various forms of radioligand therapy for metastatic prostate cancer, and consider the current and future clinical role of these strategies.
- Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and counsel appropriate patients about availability and participation.
CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.
Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — Dr Agarwal has no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:
Dr Petrylak — Consulting Agreements: Advanced Accelerator Applications, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bicycle Therapeutics, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Exelixis Inc, Gilead Sciences Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Lilly, Merck, Mirati Therapeutics Inc, Monopteros Therapeutics, Pfizer Inc, pharmaand GmbH, Pharmacyclics LLC, an AbbVie Company, Regeneron Pharmaceuticals Inc, Roche Laboratories Inc, Sanofi, Seagen Inc, UroGen Pharma; Contracted Research: Advanced Accelerator Applications, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BioXcel Therapeutics, Bristol Myers Squibb, Daiichi Sankyo Inc, Eisai Inc, Ferring Pharmaceuticals, Genentech, a member of the Roche Group, Gilead Sciences Inc, Innocrin Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Mirati Therapeutics Inc, Novartis, Pfizer Inc, pharmaand GmbH, Progenics Pharmaceuticals Inc, Replimune, Roche Laboratories Inc, Sanofi, Seagen Inc. Dr Saad — Advisory Committees and Consulting Agreements: AbbVie Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Johnson & Johnson, Merck, Novartis, Pfizer Inc, Tolmar; Contracted Research: AbbVie Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Johnson & Johnson, Merck, Novartis, Pfizer Inc; Nonrelevant Financial Relationships: Unicancer European Prostate Cancer Consortium (PEACE). Dr Shore — Consulting Agreements: Accord Healthcare, Alessa Therapeutics, Amgen Inc, Asieris Pharmaceuticals, Astellas, AstraZeneca Pharmaceuticals LP, Aura Biosciences Inc, Bayer HealthCare Pharmaceuticals, BioProtect, Bristol Myers Squibb, CG Oncology, Clarity Pharmaceuticals, Dendreon Pharmaceuticals Inc, Ferring Pharmaceuticals, FIZE Medical, GlyTherix, ImmunityBio, Incyte Corporation, Invitae, Janssen Biotech Inc, Lantheus, Lilly, Mdxhealth, Merck, Minomic, Myriad Genetic Laboratories Inc, Novartis, Nusano, Pfizer Inc, Photocure, Promaxo, Protara Therapeutics, Sumitomo Pharma America, Telix Pharmaceuticals Limited, Tolmar, Tutelix, UroGen Pharma; Stock Options/Stock — Public Company: Photocure; Nonrelevant Financial Relationships: PlatformQ Health.
CONSULTING CLINICAL INVESTIGATORS
Andrew J Armstrong, MD, ScM — Advisory Committees: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Merck, Pfizer Inc, Precede Biosciences, Sumitomo Pharma America, Telix Pharmaceuticals Limited; Consulting Agreements: Amgen Inc, Astellas, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Novartis, Pfizer Inc; Contracted Research: Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, FibroGen Inc, Janssen Biotech Inc, Merck, Novartis, Pathos, Pfizer Inc. Rana R McKay, MD FASCO — Advisory Committees and Consulting Agreements: Ambrx, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Boundless Bio, Bristol Myers Squibb, Calithera Biosciences, Caris Life Sciences, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Janssen Biotech Inc, Lilly, Merck, Myovant Sciences, Neomorph, Nimbus Therapeutics, Novartis, Pfizer Inc, Sanofi, Seagen Inc, Sorrento Therapeutics, Telix Pharmaceuticals Limited, Tempus; Contracted Research: Artera, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis Inc, Incyte Corporation, Natera Inc, Oncternal Therapeutics. Joyce O’Shaughnessy — Advisory Committees and Consulting Agreements: Aadi Bioscience, Agendia Inc, Amgen Inc, Aptitude Health, AstraZeneca Pharmaceuticals LP, BioNTech SE, Bristol Myers Squibb, Daiichi Sankyo Inc, Duality Biologics, Eisai Inc, Ellipses Pharma, Exact Sciences Corporation, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, HiberCell, Jazz Pharmaceuticals Inc, Johnson & Johnson, Lilly, Menarini Group, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Pfizer Inc, Pierre Fabre, Puma Biotechnology Inc, RayzeBio, Roche Laboratories Inc, Sanofi, Seagen Inc, Stemline Therapeutics Inc, Summit Therapeutics, Tempus, TerSera Therapeutics LLC. Sandy Srinivas, MD — Advisory Committees: Janssen Biotech Inc, Merck; Contracted Research: Bristol Myers Squibb, Merck, Pfizer Inc, Regeneron Pharmaceuticals Inc; Data and Safety Monitoring Boards/Committees: Johnson & Johnson.
MODERATOR
Dr Heath — Advisory Committees: (Personal Compensation): AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Caris Life Sciences, EMD Serono Inc, Gilead Sciences Inc, Novartis, Petauri Kinect, Pfizer Inc, Sanofi, Seagen Inc, Sumitomo Pharma America; Advisory Committees (to Institution): Janssen Biotech Inc; Consulting Agreements (Personal Compensation): Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Novartis, Sanofi; Consulting Agreements (to Institution): AstraZeneca UK, Novartis; Contracted Research (Grants): K36 Therapeutics, Novartis; Contracted Research (Research Support to Institution): Amgen Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BioXcel Therapeutics, Bristol Myers Squibb, Calithera Biosciences, Caris Life Sciences, Corcept Therapeutics Inc, Corvus Pharmaceuticals, Daiichi Sankyo Inc, Eisai Inc, Exelixis Inc, Fortis Therapeutics, Gilead Sciences Inc, GSK, Harpoon Therapeutics, Infinity Pharmaceuticals Inc, iTeos Therapeutics, Janssen Research and Development, K36 Therapeutics, Merck, MSD, Mirati Therapeutics Inc, Modra Pharmaceuticals, Novartis, Oncolys Biopharma, Peloton Therapeutics Inc, a wholly-owned subsidiary of Merck & Co Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, POINT Biopharma, Roche Laboratories Inc, Seagen Inc; Presenter/Co-Moderator: Curio Science; Speakers Bureaus: Sanofi; Steering Committees (Uncompensated): ORIC Pharmaceuticals; Travel Support: AstraZeneca UK; Nonrelevant Financial Relationships: Calibr-Skaggs Institute for Innovative Medicines.
EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.
Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Merck.
Walter E Washington Convention Center
801 Allen Y Lew Place NW
Washington, DC 20001
Phone: (202) 249-3000
Meeting Room
Ballroom A, Third Level
Directions
The Walter E Washington Convention Center is the main venue for the 2026 AUA Annual Meeting.
Registration is now closed.